


Tapotoclax

Cat. No.:	HY-101565		
CAS No.:	1883727-34-1		
Molecular Formula:	$C_{33}H_{41}ClN_2O_5S$		
Molecular Weight:	613.21		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (101.92 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		1.6308 mL	8.1538 mL	16.3076 mL
		5 mM		0.3262 mL	1.6308 mL	3.2615 mL
		10 mM		0.1631 mL	0.8154 mL	1.6308 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Tapotoclax (AMG-176) is a potent, selective and orally active MCL-1 inhibitor, with a K_i of 0.13 nM ^{[1][2]} .
IC ₅₀ & Target	Mcl-1 0.13 nM (K _i)
In Vitro	Tapotoclax is an inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (K_i =0.13 nM), with potential pro-apoptotic and antineoplastic activities. Upon administration, Tapotoclax binds to and inhibits the activity of MCL-1. This

disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells^{[1][2]}.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Rep. 2023 Sep 27;42(10):113176.
- Biomed Pharmacother. 2023 Oct 19;168:115738.
- Int J Cancer. 2020 Oct 15;147(8):2176-2189.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Caenepeel S, et al. AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies. Cancer Discov. 2018 Sep 25. pii: CD-18-0387.

[2]. Garner TP, et al. Progress in targeting the BCL-2 family of proteins. Curr Opin Chem Biol. 2017 Aug;39:133-142.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA